- In May 2024, Takara Bio USA Inc. introduced the Lenti-X Transduction Sponge, a dissolvable microfluidic transduction enhancer designed for in vitro lentivirus-mediated gene delivery. This innovation simplifies workflows and ensures high transduction efficiency across various cell types, thereby advancing research in gene and cell therapy. This launch reinforces Takara Bio’s contribution to precision genetic engineering
- In May 2024, Fluidic Sciences Ltd. officially entered the market and relaunched the Fluidity One-M instrument, a device designed to measure protein-protein interactions in solution using Microfluidic Diffusional Sizing (MDS) technology. This tool enhances capabilities in membrane protein studies, vaccine response analysis, and therapeutic antibody research. The launch expands options for scientists in advanced biopharmaceutical R&D
- In February 2023, Amar Equipment, an Indian company, unveiled NanoMake, a microfluidics-based device aimed at supporting preclinical research on mRNA vaccines for COVID-19. The innovation aims to strengthen India's capabilities in biomedical research and pandemic preparedness. This product enhances Amar Equipment’s role in global vaccine development initiatives
- In November 2022, Nagi Bioscience, a Swiss startup, began testing drugs on Caenorhabditis elegans (a model organism) using automated microfluidic platforms to accelerate safety testing of drugs and chemicals. The initiative combines automation with micro-scale biology to fast-track pharmaceutical and environmental research. This development signals a shift toward faster and more ethical drug testing technologies
- In October 2022, Standard BioTools, Inc. launched the X9 Real-time PCR System, a genomics instrument leveraging microfluidics to deliver high-throughput and efficient data output in a single run. This addition to their portfolio supports diverse genomic applications in clinical and research settings. The product strengthens the company’s competitive edge in the microfluidic genomics space
